Muhammad Lodhi

Dr. Muhammad Lodhi


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in ACS Omega
Verified
Journal Article
Open access
FBFarida Begum
Farida Begum
MYMuhammad Yousaf
Muhammad Yousaf
SISajid Iqbal
Sajid Iqbal
NUNazif Ullah
Nazif Ullah
AHAnwar Hussain
Anwar Hussain
Ahmed Al-HarrasiAhmed Al-Harrasi
Ahmed Al-Harrasi
Alzheimer's disease (AD) is a neurological disease that disturbs the memory, thinking skills, and behavior of the affected person. AD is a complex disease caused by the breakdown of acetylcholine via acetylcholinesterase (AChE). The present study aimed to assess the synthetic inhibitors of AChE that could be used to treat AD. For this purpose, synthetic compounds of oxadiazole derivatives (15-35) were evaluated and identified as promising inhibitors of AChE, exhibiting IC50 varying between 41.87 ± 0.67 and 1580.25 ± 0.7 μM. The kinetic parameters indicated that all the studied compounds bind to the allosteric site and decrease the efficiency of the AChE enzyme. In silico docking analysis showed that the majority of the compounds interact with the anionic subsite and Per-Arnt-Sim domain of AChE and are stabilized by various bonds including π-π and hydrogen bonding. The stability of the most potent compounds 16 and 17 with AChE interaction was confirmed by molecular dynamics simulations. Moreover, all compounds exhibited concentration-dependent calcium (Ca2+) antagonistic and spasmolytic activities. Among the whole series of oxadiazole derivatives, compounds 16 and 17 displayed the highest activities on spontaneous and potassium (K+)-induced contraction. Therefore, the AChE inhibitory potential, cytotoxicity safe profile, and Ca2+ antagonistic ability of these compounds make them potential therapeutic agents against AD and its associated problems in the future.

4 March 2017 in Hemoglobin
Verified
Journal Article
Closed access
RMRaj Muhammad
Raj Muhammad
MSMuhammad Shakeel
Muhammad Shakeel
SRShoaib U. Rehman
Shoaib U. Rehman
MLMuhammad Lodhi
Muhammad Lodhi
β-Thalassemia (β-thal) is the most prevalent hereditary blood disorder in Pakistan with a carrier rate of 5.0–8.0%. The homozygous affected children require frequent blood transfusions for their survival. This autosomal recessive disease can only be prevented through awareness programs, carrier screening, mutation detection, genetic counseling and prenatal diagnosis (PND). The present study aimed to determine the prevalence of various mutations causing β-thal and also to detect carriers of these mutations in families living in the Mardan Division, Khyber Pakhtunkhwa (KP) Province, Pakistan. The study was conducted at the Department of Biochemistry, Abdul Wali Khan University Mardan, Pakistan. Blood samples of β-thalassemic families were collected from various transfusion centers in Mardan Division. Using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique, all samples were analyzed for the six most common mutations causing β-thal in this area. Six different mutant primers for the detection of different mutations were used. The most common mutations detected in thalassemic patients were frameshift codons (FSC) 8/9 (+G) (HBB: c.27_28insG), codons 41/42 (–TTCT) (HBB: c.126_129delCTTT), and IVS-I-5 (G>C) (HBB: c.92+5G>C). The predominant mutation for carrying the mutant genes for β-thal were FSC 8/9, IVS-I-5, codons 41/42, IVS-I-1. It was also found that 66.7% of marriages were consanguineous. The FSC 8/9 mutation was found to be the most common β-thal mutation with a frequency of 44.4%. This research project provides a strong incentive for the establishment of large scale mutation detection and PND services in the Mardan Division.

9 August 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
FBFarida Begum
Farida Begum
Najeeb Ur RehmanNajeeb Ur Rehman
Najeeb Ur Rehman
Ajmal KhanAjmal Khan
Ajmal Khan
SISajid Iqbal
Sajid Iqbal
RPRehan Zafar Paracha
Rehan Zafar Paracha
MLMuhammad Lodhi
Muhammad Lodhi
Alzheimer’s is a type of dementia that affects the affected person’s thinking, memory, and behavior. It is a multifactorial disease, developed by the breakdown of the neurotransmitter acetylcholine via acetylcholinesterase (AChE). The present study was designed to evaluate potential inhibitors of acetylcholinesterase that could be used as a therapeutic agent against Alzheimer’s disease (AD). For this course, synthetic compounds of the Schiff bases class of 2-mercaptobenzimidazole hydrazone derivatives (9–14) were determined to be potent acetylcholinesterase inhibitors with IC50 values varying between 37.64 ± 0.2 and 74.76 ± 0.3 μM. The kinetic studies showed that these are non-competitive inhibitors of AChE. Molecular docking studies revealed that all compounds accommodate well in the active site and are stabilized by hydrophobic interactions and hydrogen bonding. Molecular dynamics (MD) simulations of selected potent inhibitors confirm their stability in the active site of the enzyme. Moreover, all compounds showed antispasmodic and Ca2+ antagonistic activities. Among the selected compounds of 2-mercaptobenzimidazole hydrazone derivatives, compound 11 exhibited the highest activity on spontaneous and K+-induced contractions, followed by compound 13. Therefore, the Ca2+ antagonistic, AChE inhibition potential, and safety profile of these compounds in the human neutrophil viability assay make them potential drug candidates against AD in the future.

2 December 2011 in Chemical Biology & Drug Design
Verified
Journal Article
Open access
PDF file
AWAbdul Wadood
Abdul Wadood
Syed Abid AliSyed Abid Ali
Syed Abid Ali
RSRabia Sattar
Rabia Sattar
MLMuhammad Lodhi
Muhammad Lodhi
Zaheer Ul-HaqZaheer Ul-Haq
Zaheer Ul-Haq
In addition to catalytic action, snake venom phospholipase A2 induces several pharmacological effects including neurotoxicity, cardiotoxicity as well as anti‐coagulant and anti‐platelet aggregation effects. Therefore, strategy to identify dual inhibitor for this enzyme will be of much importance in medical research. In this paper, structure‐based pharmacophore mapping, molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions were employed in a virtual screening strategy to identify new hits for dual inhibition of anti‐coagulation and inflammation of phospholipase A2. A structure‐based pharmacophore map was modeled which comprised of important interactions as observed in co‐crystal of phospholipase A2 and its dual inhibitor indomethacin. The generated model was used to retrieve molecules from ChemBridge, a free database of commercially available compounds. A total of 381 molecules mapped on the developed pharmacophore model from ChemBridge database. The hits retrieved were further screened by molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions using Genetic Optimization for Ligand Docking and moe. Based on these results, 32 chemo‐types molecules were predicted as potential lead scaffolds for developing novel, potent and structurally diverse dual inhibitor of phospholipase A2.

1 January 2021 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
FKFarman Ali Khan
Farman Ali Khan
SSShahbaz Shamim
Shahbaz Shamim
NUNisar Ullah
Nisar Ullah
MLMuhammad Lodhi
Muhammad Lodhi
KKKhalid Mohammed Khan
Khalid Mohammed Khan
Ajmal KhanAjmal Khan
Ajmal Khan

27 October 2021 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
KRK. Rubab
K. Rubab
MAM. A. Abbasi
M. A. Abbasi
ARAziz- Ur- Rehman
Aziz- Ur- Rehman
SSS. Z. Siddiqui
S. Z. Siddiqui
SSSyed Adnan Ali Shah
Syed Adnan Ali Shah
IAI. Ahmad
I. Ahmad